Case Studies

Challenge: Our client, a publicly listed biotech company, was considering a merger with another publicly listed firm. To further initial discussions, a third-party valuation was commissioned on the...

Challenge: A prominent researcher at an academic research institution had developed a class of small molecule compounds with in vitro antiviral activity against a family of RNA viruses. The...

Challenge: A South Korean consulting firm required support in exploratory partner outreach in the US and Europe. Alacrita was commissioned to use its expertise in pharma licensing and deal-making in...

Challenge: A privately-funded preclinical stage biotech company asked Alacrita for a valuation of their lead pipeline agent for use in discussions with VC investors regarding their next financing...

Challenge: A PE fund was looking at the potential purchase of a package of minority holdings in a portfolio of biotech companies on the secondary market. The fund approached Alacrita to conduct a due...

Challenge: For a competitive M&A transaction, Alacrita was commissioned to conduct a technical due diligence of a major public drug delivery contract development and manufacturing organization. This...

Challenge: A family office was considering an investment in a US-based biotech company developing a product aimed at improving impaired oxygen transport in COVID-19 patients. Using its expert...

Challenge: A VC firm was interested in a US-based drug repurposing company and asked Alacrita to perform a high level technical due diligence exercise to help the firm make an informed decision about...

Challenge: A clinical stage biotech company developing treatments for Alzheimer's disease was looking for a valuation of its Phase II-ready therapeutic drug. The drug was a re-purposed combination of...

Challenge: Our client, a VC firm based in Dubai, was planning to invest in a US-based therapeutics company and asked Alacrita to perform a technical DD. The target company was using a proprietary...

Challenge: A biopharmaceutical company with a focus on immunomodulatory compounds was looking to expand the application of its lead product in oncology, specifically, by adapting the product to...

Challenge: A venture capital firm was interested in an independent indication selection strategic assessment of a clinical stage small molecule oncology asset they had invested in, based on the...